2023-07-21 07:18:54
The clinical trial of a vaccine once morest skin cancer has obtained encouraging results, to the point of considering its marketing.
Every year in France, 80,000 people discover they have skin cancer. If the most common forms are basal cell carcinomas (70% of cases), more serious forms can occur. In particular, they can generate metastases, ie extensions that spread throughout our body.
To treat this type of cancer, there are now several options such as surgery, radiotherapy or immunotherapy. In addition to this treatment, health professionals can prescribe a suitable diet. But within a few years, a new treatment that is simpler to prescribe but just as effective might be proposed.
In the United Kingdom, a clinical trial concerning the administration ofa disease-fighting vaccine is currently being conducted. And the results are so promising that they are considering returning it available to the general public by 2028.
A reduction of more than 40% in the risk of death or recurrence
The results and the hopes of the researchers were relayed by the British newspaper Daily Mail on July 15th. However, this experiment has only been underway since the beginning of the year. But be careful because you have to keep in mind that this vaccine is not a preventive treatment. In fact, and contrary to how other vaccines work, it is administered in patients already diagnosed.
Its objective is to better prepare the patient’s immune system for treatment coming. It also helps to help the body recognize changes in cancer cells. In addition to improving the effectiveness of additional treatments, this vaccine would also reduce the risk of recurrence.
Moreover, the results shared by the team evoke a 44% reduction in the risk of melanoma or recurrence.
Each treatment personalized and adapted to the skin cancer during these clinical trials
However, this would not be the only promising vaccine being tested. Indeed, the clinical trial includes more than 10,000 volunteers who test treatments once morest several types of cancer. But the treatment once morest skin cancer has a particularity: each vaccine is personalized according to each patient.
As for the dosage, it is currently one dose every 3 weeks for a period of 9 months. And as the vaccine prepares the body for the treatment, the volunteers involved also participated in immunotherapy sessions. According to Dr. Jane Healy (responsible for this clinical trial), it is “the first cancer vaccine of this type to give such good results. »
Very effective on melanoma, the vaccine has yet to be tested on other forms of skin cancer. But if the trial is very conclusive, its validation by the health authorities will only be a matter of time.
1689957784
#Curing #skin #cancer #vaccine
